This retrospective cohort study of 1,095 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates that the pattern of metastatic spread is strongly linked to clinical outcome and genomic detection. Patients with lung-only metastases had a significantly prolonged median overall survival of 57.6 months compared to roughly 19.5 months in patients with liver-involved disease. Tissue genomic profiling identified lower TP53 mutation frequencies and higher GNAS mutation rates in non-liver and lung-only metastases. Crucially, liquid biopsy (n = 240) showed markedly lower detection rates for KRAS (10%) and TP53 (23%) in lung-only disease, underscoring that tissue-based sequencing must be prioritized in these patients to guide KRAS-directed therapeutic decisions.
This prospective study evaluated the prognostic significance of KRAS-mutant circulating tumor DNA (ctDNA) in patients with localized pancreatic ductal adenocarcinoma (PDAC). Analyses compared detection by next-generation sequencing (NGS) and digital droplet PCR (ddPCR) at various stages of perioperative treatment. Results indicated that the more sensitive ddPCR detected KRAS-mutant ctDNA in a greater proportion of patients than NGS. Detection by either method was associated with shorter overall survival, with ddPCR providing superior prognostic discrimination by identifying additional patients with poor outcomes missed by NGS. Integrating both methods could enhance perioperative risk stratification.
This study investigates resistance mechanisms to KRAS G12D inhibitors, such as HRS-4642, in pancreatic ductal adenocarcinoma (PDAC). Researchers identified the reactivation of the unfolded protein response (UPR) via the MEK/ERK pathway as a key mechanism of acquired resistance, observed in vitro, in vivo, and in patients. To overcome this resistance, a combination therapy with nimotuzumab was tested, demonstrating strong synergy and resistance reversal. Nimotuzumab sustained the suppression of the MEK/ERK/UPR axis while exacerbating endoplasmic reticulum stress, leading to profound cellular damage. These findings suggest a promising combined strategy for PDAC patients harboring KRAS G12D mutations.
This phase 3 study evaluated the efficacy and safety of daraxonrasib, a multiselective RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients were randomized to receive either daraxonrasib or investigator’s choice chemotherapy. Results demonstrated significantly longer overall survival and progression-free survival with daraxonrasib compared to chemotherapy, both in the RAS G12 mutated population and the overall population. Daraxonrasib also showed a favorable safety profile, with a significantly lower rate of treatment discontinuation due to adverse events compared to chemotherapy.
This study aimed to improve risk stratification for early liver metastasis in pancreatic ductal adenocarcinoma (PDAC) by integrating single-cell analysis and digital pathology. Researchers combined single-cell RNA sequencing (scRNA-seq) data from primary and metastatic PDAC tumors with transcriptomic, clinical, and H&E image data. They identified a four-gene signature (ARHGAP18, ASPH, EIF4EBP1, LY6D) associated with metastasis, which correlated with features extracted from pathological images. A pathology model based on these features demonstrated prognostic stratification capabilities in internal and external cohorts. This approach proposes a genotype-to-phenotype workflow linking scRNA-seq-derived metastatic features to routine histopathological images.